Takeda Pharmaceutical Company Limited

Yoshihide Tomata

Satoshi Yamamoto

Junya Shirai

Yoshiyuki Fukase

Atsuko Ochida

Tsuneo Oda

Naoki Ishii

Shoji Fukumoto

Mitsunori Kono

Hidekazu Tokuhara

Tomoya Yukawa

Takashi Imada

Ayumu Sato

Michiko Tawada

Yusuke Sasaki

Tatsuki Koike

Yasutaka Hoashi

Yasushi Hattori

Minoru Nakamura

Tsuneo Yasuma

Yuichi Kajita

Makoto Kamata

Norihito Tokunaga

Hiroyuki Watanabe

Yuhei Miyanohana

Nobuyuki Takakura

Kazuko Yonemori

Takahiro Matsumoto

Tohru Miyazaki

Koichiro Fukuda

Shuji Kitamura

Tatsuhiko Fujimoto

Takafumi Takai

Yoshihiro Banno

Tetsuya Tsukamoto

Shogo Marui

Yoshito Terao

Kentaro Rikimaru

Yuji Ishichi

Hideyuki Nakagawa

Hiromichi Sugimoto

Minoru Ikoma

Sachie Morimoto

Shotaro Miura

Mitsunori Kouno

Kei Masuda

Ryokichi Koyama

The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

Heterocyclic compound and application thereof

The present invention relates to compound (I) or a salt thereof which has a RORγt inhibitory action. In the formula (I), each symbol is as defined in the specification.

Heterocyclic amide compounds having an RORvt inhibitory action

The present invention relates to compound (I) or a salt thereof which has a ROR&#x3b3;t inhibitory action. In the formula (I), each symbol is as defined in the specification. 

Heterocyclic amide compounds having RORyT inhibitory action

Amide compound

Provided are heterocyclic compounds having a ROR&#x3b3;t inhibitory action represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof. 

Heterocyclic compounds and their use as retinoid-related orphan receptor (ROR) gamma-T inhibitors

The present invention relates to compound (I) or a salt thereof which has a ROR&#x3b3;t inhibitory action. wherein each symbol is as defined in the specification.

Heterocyclic compound

The problem of the present invention is to provide a compound having a superior ROR&#x3b3;t inhibitory action, and useful as a prophylactic or therapeutic agent for psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, multiple sclerosis, uveitis, asthma, ankylopoietic spondylarthritis, systemic lupus erythematosus, chronic obstructive pulmonary disease or the like. The present invention relates to a compound represented by the formula (I): [wherein each symbol is as described in the DESCRIPTION] or a salt thereof, which has an ROR&#x3b3;t inhibitory action, and useful as a prophylactic or therapeutic agent for psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, multiple sclerosis, uveitis, asthma, ankylopoietic spondylarthritis, systemic lupus erythematosus, chronic obstructive pulmonary disease or the like.

The present invention provides a heterocyclic compound having an ROR&#x3b3;t inhibitory action. The present invention relates to a compound represented by the formula (I): whereinAr is a the partial structure (1) to the partial structure (5),Q is a bivalent group selected from the group consisting of (Ia)-(If), andB is a ring optionally having substituent(s),or a salt thereof.

The present invention provides a heterocyclic compound having a ROR&#x3b3;t inhibitory action. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification.or a salt thereof.

A heterocyclic compound having an ROR&#x3b3;t inhibitory activity, which is a compound of formula (I) or a salt thereof is provided. The compound has ring A, which is an optionally substituted cyclic group and is bound to a pyrazole ring though Q. Q is a bond, optionally substituted Calkylene, optionally substituted Calkenylene, or optionally substituted Calkynylene. Ris a substituent. Ring B is a thiazole ring, an isothiazole ring or a dihydrothiazole ring, each of which is optionally further substituted by a substituent in addition to R. Ris an optionally substituted cyclyl-carbonyl-Calkyl group, an optionally substituted aminocarbonyl-Calkyl group, an optionally substituted cyclyl-Calkyl group, an optionally substituted cyclyl-Calkylamino-carbonyl group, an optionally substituted aminocarbonyl-Calkenyl group, an optionally substituted Calkylcarbonylamino-Calkyl group, an optionally substituted cyclyl-aminocarbonyl group, an optionally substituted cyclyl-carbonyl group or an optionally substituted non-aromatic heterocyclic group.

The present invention provides a fused heterocyclic compound having an ROR&#x3b3;t inhibitory action. The present invention relates to a compound represented by the formula (I'): wherein each symbol is as defined in the specification, provided that 2-(2-((4-cyanophenyl)amino)-2-oxoethoxy)-N-(9-ethyl-9H-carbazol-3-yl)acetamide and N-(4-cyanophenyl)-N&#x2032;-(9-ethyl-9H-carbazol-3-yl)-3-methylpentanediamide are excluded, or a thereof.

Condensed heterocyclic compound

The present invention provides a heterocycle derivative having a superior amyloid &#x3b2; production inhibitory activity and/or a superior &#x3b3;-secretase modulation activity, and use thereof. A compound represented by the formula (I): wherein each symbol is as defined in the present specification, or a salt thereof.

Heterocyclic compound and use thereof

Growing community of inventors

Kanagawa, Japan

Yoshihide Tomata